Access to anti-retroviral drugs, male in Algeria

Algeria: Access to anti-retroviral drugs, male was 68.0% in 2024. ◆ Volatile

Latest (2024)
68.0%
Change on year
down 4.2%
World rank
73rd
of 141 countries
All-time high
72.0%
in 2021
All-time low
8.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Algeria, 2000–2024

0204060802000201220242000: 8 %2001: 10 %2002: 10 %2003: 11 %2004: 13 %2005: 14 %2006: 19 %2007: 17 %2008: 16 %2009: 15 %2010: 19 %2011: 21 %2012: 25 %2013: 30 %2014: 36 %2015: 46 %2016: 55 %2017: 60 %2018: 65 %2019: 69 %2020: 69 %2021: 72 %2022: 68 %2023: 71 %2024: 68 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Algeria is 68.0%, measured in 2024.

Compared with earlier readings it is down 4.2% on the previous year and up 88.9% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Algeria peaked at 72.0% in 2021 and was at its lowest, 8.0%, in 2000.

That places Algeria 73rd out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Algeria, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Algeria, 2000 to 2024.
Year % Change
2000 8.0%
2001 10.0% +25.0%
2002 10.0% +0.0%
2003 11.0% +10.0%
2004 13.0% +18.2%
2005 14.0% +7.7%
2006 19.0% +35.7%
2007 17.0% -10.5%
2008 16.0% -5.9%
2009 15.0% -6.2%
2010 19.0% +26.7%
2011 21.0% +10.5%
2012 25.0% +19.0%
2013 30.0% +20.0%
2014 36.0% +20.0%
2015 46.0% +27.8%
2016 55.0% +19.6%
2017 60.0% +9.1%
2018 65.0% +8.3%
2019 69.0% +6.2%
2020 69.0% +0.0%
2021 72.0% +4.3%
2022 68.0% -5.6%
2023 71.0% +4.4%
2024 68.0% -4.2%

Averages by decade

DecadeAverage LowestHighest Years
2000s 13.3% 8.0% 19.0% 10
2010s 42.6% 19.0% 69.0% 10
2020s 69.6% 68.0% 72.0% 5

Countries ranked near Algeria

  1. 72 Côte d'Ivoire 69.0% compare
  2. 73 Burkina Faso 68.0% compare
  3. 73 Dominican Republic 68.0% compare
  4. 73 Estonia 68.0% compare
  5. 73 Greece 68.0% compare

See the full ranking of 160 places →

More gender data for Algeria

All data for Algeria →

Frequently asked questions

What is access to anti-retroviral drugs, male in Algeria?
Access to anti-retroviral drugs, male in Algeria was 68.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Algeria?
The highest recorded value was 72.0% in 2021.
What is the lowest access to anti-retroviral drugs, male recorded in Algeria?
The lowest recorded value was 8.0% in 2000.
How does Algeria rank for access to anti-retroviral drugs, male?
Algeria ranks 73rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Algeria?
Over the last ten years it is up 88.9%. The long-run trend across the full record is volatile.
Where does this Algeria data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Algeria. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/algeria/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/algeria/">Access to anti-retroviral drugs, male in Algeria</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.